CSL Behring Launches My Access™ Cost Share Program during Hemophilia Awareness
My Access Offers Out-of-Pocket Payment Assistance to Eligible People in the
United States Who Are Treating Hemophilia A or von Willebrand Disease with a
CSL Behring Therapy
KING OF PRUSSIA, Pa., March 25, 2014
KING OF PRUSSIA, Pa., March 25, 2014 /PRNewswire/ --People who are treating
hemophilia A or von Willebrand Disease (VWD) with a CSL Behring therapy may
now be eligible for financial support through the company's My Access™ cost
share program. My Access helps hemophilia A and VWD patients, who have
private insurance, cover the out-of-pocket costs, up to $12,000, associated
"CSL Behring has a long history of providing medical innovations and
supportive services that make a meaningful difference in the lives of people
with a bleeding disorder and those who care for them," said Lynne Powell,
Senior Vice President, North America Commercial Operations, CSL Behring. "My
Access serves as another example of CSL Behring's longstanding commitment to
people who are living with a bleeding disorder and we are proud to officially
launch this program during Hemophilia Awareness Month."
My Access is available through CSL Behring's My Source™ program. For My Access
participants, CSL Behring will coordinate with specialty pharmacies,
hemophilia treatment centers and outpatient hospital services to cover, up to
$12,000 per year, out-of-pocket expenses associated with their CSL Behring
hemophilia A or VWD therapy. Participants can reenroll every year. My Access
is open to U.S. residents only. Participants must have U.S.-based private
insurance that covers their CSL Behring therapy. Individuals covered by state
or federally funded programs, such as Medicare, Medicaid and Veterans Health
Insurance, are not eligible.
"My Access represents CSL Behring's thorough understanding of the challenges
facing the bleeding disorders community," said Jesse Schrader, a patient with
hemophilia A, who is enrolled in My Access and is a member of CSL Behring's
Gettin' in the Game^SM program. "The company's dedication to addressing the
community's needs is one of the reasons why I choose to partner with CSL
For more information, or to enroll in My Access, please visit
www.MySourceCSL.com or call the My Source Hotline at 1-800-676-4266 and speak
with a My Source Care Coordinator. My Access is administered by a third party
patient services organization.
About My Source™
CSL Behring created My Source to provide members of the bleeding disorders
community with a single source of information that will enhance their
treatment experience. My Source was also designed to meet the specific needs
and preferences of each patient by providing customized information each
timehe or shevisits. My Source offers:
oEducation opportunities that provide members of the bleeding disorders
community with information about hemophilia and von Willebrand Disease
oFinancial support programs, like My Access, to help ensure individuals are
able to access their treatment
oCommunity connections that allow members of the bleeding disorders
community to share experiences with one another, both online and in person
About Hemophilia A
Hemophilia is an inherited bleeding disorder characterized by prolonged or
spontaneous bleeding, especially into the muscles and joints. In nearly all
cases, it affects only males. The disorder is caused by deficient or defective
blood coagulation proteins known as factor VIII or IX. The most common form of
the disorder is hemophilia A, or classic hemophilia, in which the clotting
factor VIII is either deficient or defective. Hemophilia A affects
approximately 1 in 5,000 to 10,000 people.
About von Willebrand Disease
Von Willebrand Disease (VWD), the most common hereditary bleeding disorder in
the United States, affects approximately 1 to 2 percent of the U.S.
population. It is caused by a deficiency or abnormality of von Willebrand
factor, a protein in the blood that is necessary for normal blood clotting.
Men and women are equally likely to be affected by the disorder. VWD is
classified by type of defect, ranging from Type I (the most common and
mildest) to Type III (the least common and most severe).
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed
to saving lives and improving the quality of life for people with rare and
serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders
including hemophilia and von Willebrand disease, primary immune deficiencies,
hereditary angioedema and inherited respiratory disease, and neurological
disorders in certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent hemolytic
diseases in the newborn. CSL Behring operates one of the world's largest
plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL
Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne,
Australia. For more information, visit www.cslbehring.com.
Senior Manager, Public Relations & Communications
SOURCE CSL Behring
Press spacebar to pause and continue. Press esc to stop.